ARDS

1,249 views 73 slides Jan 26, 2021
Slide 1
Slide 1 of 73
Slide 1
1
Slide 2
2
Slide 3
3
Slide 4
4
Slide 5
5
Slide 6
6
Slide 7
7
Slide 8
8
Slide 9
9
Slide 10
10
Slide 11
11
Slide 12
12
Slide 13
13
Slide 14
14
Slide 15
15
Slide 16
16
Slide 17
17
Slide 18
18
Slide 19
19
Slide 20
20
Slide 21
21
Slide 22
22
Slide 23
23
Slide 24
24
Slide 25
25
Slide 26
26
Slide 27
27
Slide 28
28
Slide 29
29
Slide 30
30
Slide 31
31
Slide 32
32
Slide 33
33
Slide 34
34
Slide 35
35
Slide 36
36
Slide 37
37
Slide 38
38
Slide 39
39
Slide 40
40
Slide 41
41
Slide 42
42
Slide 43
43
Slide 44
44
Slide 45
45
Slide 46
46
Slide 47
47
Slide 48
48
Slide 49
49
Slide 50
50
Slide 51
51
Slide 52
52
Slide 53
53
Slide 54
54
Slide 55
55
Slide 56
56
Slide 57
57
Slide 58
58
Slide 59
59
Slide 60
60
Slide 61
61
Slide 62
62
Slide 63
63
Slide 64
64
Slide 65
65
Slide 66
66
Slide 67
67
Slide 68
68
Slide 69
69
Slide 70
70
Slide 71
71
Slide 72
72
Slide 73
73

About This Presentation

ICU


Slide Content

ARDS Evidence based strategies DR. AMITH SREEDHARAN Aster mims , Kannur

History In 1967, Ashbaugh and colleagues reported the clinical characteristics of 12 patients with sudden respiratory failure that they called ARDS  No underlying cardiac or pulmonary disease Rapidly developed acute hypoxemia, stiff lungs, and diffuse bilateral alveolar infiltrates on chest x-ray a few days following exposure to a precipitating factor. Autopsies revealed a characteristic histological pattern of diffuse alveolar damage (DAD) including hyaline membrane formation, oedema , cell necrosis, or fibrosis ( Ashbaugh et al. 1967 )

10% ICU PATIENTS 23% MECHANICALLY VENTILATED PATIENTS MORTALITY IN SEVERE ARDS – 46% COGNITIVE DECLINE ,DEPRESSION ,PTSD ,MUSCLE WEAKNESS

FIVE KEY CLINICAL FEATURES PRESENCE OF DEFINED RISK FACTOR SEVERE HYPOXEMIA REFRACTORY TO SUPPLEMENTAL OXYGEN BILATERAL PULMONARY INFILTRATES REDUCED LUNG COMPLIANCE ABSENCE OF CHF

LUNG INJURY SCORE MURRAY 1988 P/F RATIO PEEP COMPLIANCE RADIOGRAPHIC DISTRIBUTION INVALIDATED AS A MARKER OF MORTALITY

First clinical definition - AECC (1994) Acute onset of hypoxemia PaO 2   to FiO 2   ratio ≤ 200 mmHg regardless of PEEP level, Presence of bilateral infiltrates on chest radiograph, and Pulmonary artery wedge pressure ≤ 18 mmHg or no clinical signs of cardiogenic pulmonary oedema ALI ( acute lung injury) ARDS

CRITIQUE VARIABILITY IN PLAIN FILM INTERPRETATION POOR CORRELATION WITH CT CLINICAL ARDS PATIENTS HAD ELEVATED PCWP NO STANDARDISATION OF PEEP ALI ARDS DISTINCTION - ? SIGNIFICANCE

BERLIN definition (2012)

Timing of onset By definition, respiratory symptoms must commence within 7 days of a clinical insult Disease processes developing over several weeks like idiopathic pulmonary fibrosis, nonspecific interstitial pneumonitis and granulomatosis with polyangiitis can be excluded by accurately timing the respiratory symptoms

Diseases with acute onset that may mimic ARDS CONGESTIVE HEART FAILURE INTERSTITIAL LUNG DISEASE CONNECTIVE TISSUE DISEASE DIFFUSE ALVEOLAR HEMORRHAGE – ANTI GBM DRUG INDUCED LUNG DISEASE ENDOBRONCHIAL TUBERCULOSIS MALIGNANCY A complete diagnostic workup should include Echo , BAL and chest CT scan

ARDS is an acute inflammatory lung condition ARDS is not a disease Always precipitated by an underlying process

Pathophysioogy ARDS is characterized by a marked reduction in lung compliance DAD is the morphological hallmark of the lung in ARDS Diffuse alveolar damage is defined by the presence of hyaline membranes associated with interstitial oedema , cell necrosis and proliferation and then fibrosis at a later stage  

INTERSTITIAL AND ALVEOLAR EDEMA TO FIBROSIS EXUDATIVE PHASE – INITIAL RESPONSE TO INJURY INNATE IMMUNE CELL MEDIATED DAMAGE OF ALVEOLAR ENDOTHELIAL AND EPITHELIAL BARRIERS – EDEMA FLUID WITHIN ALVEOLUS PROLIFERATIVE PHASE - REPAIR PROCESS – RESTORE ALVEOLAR ARCHITECTURE FIBROTIC PHASE - FINAL PHASE – NOT IN ALL PROLONGED MECHANICAL VENTILATION AND INCREASED MORTALITY

Normal lung Hyaline membranes Fibrosis Alveolar hemorrhage

Mechanisms of hypoxemia in ARDS Loss of lung volume due to alveolar oedema and collapse intrapulmonary shunt and marked alteration in (VA/Q ratio) Surfactant deficiency impairment to the hypoxic pulmonary vasoconstriction response Pulmonary hypertension and positive pressure ventilation Opening of patent foramen ovale intracardiac shunt Increase in the physiological dead space occurs Alteration in lung diffusion

Traditional ventilator settings TV 12 – 15 ml/kg PEEP 0 - 5 CM H20 FiO2 0.8 - 1.0 PaCO2 < 50, PO2 > 80, spO2 > 98% Ventilator induced lung injury(VILI)

Volu trauma Ventilator induced lung injury( VILI ) Baro trauma Atelecto trauma Bio trauma Oxygen toxicity

“Baby lung” Using CT scan, Gattinoni found that compliance correlated with the normally aerated lung and that the specific compliance ( compliance divided by functional residual capacity ) was actually norma l. The "baby lung" is a physiological concept The remaining normally aerated lung accessible to ventilation is considerably reduced and of similar size as that of a baby  ARDS lung is not "stiff" but instead small , with nearly normal intrinsic elasticity

“Baby lung” concept

Volutrauma

Effect of PEEP

TREATMENT STRATEGIES

Oxygenation strategies The first-line strategy in supporting hypoxemic patients is to provide oxygen oxygen mask oxygen mask plus reservoir High flow canula – 1 st line strategy for oxygenation

HFNC

The FLORALI study a small multicenter , open-label trial acute hypoxaemic respiratory failure and without hypercapnia, treatment with high-flow nasal oxygen, standard face mask oxygen, or non-invasive ventilation did not result in a significantly different intubation rates. There was a significant difference in favour of high-flow nasal oxygen in 90 day mortality (Frat et al, 2015; FLORALI study)

NIV No strong evidence for the use of noninvasive ventilation ( NIV) Intubation rates of 40-50% in cases of moderate and severe ARDS Risk of delaying intubation by masking signs of respiratory distress Worsening VILI   poor tolerance of the facemask is frequent

When to intubate? Whatever oxygenation strategy is used, intubation should not be delayed . RR > 35-40 breaths/min Clinical signs of respiratory distress Severe hypoxemia defined as PaO 2   < 60 mm Hg or SpO 2   < 90% despite high FiO 2   Respiratory acidosis, and copious secretions Non-respiratory indications for invasive ventilation are altered consciousness and the occurrence of shock

Targets of mechanical ventilation To achieve adequate gas exchange whilst avoiding VILI

Lung protective ventilation Low VTs ( 4 - 6 ml/kg of ideal body weight) High PEEP levels ( 11- 16 cm h2O) Strict monitoring of plateau pressure to avoid exceeding 30 cm H2O

Mode of ventilation Worldwide assist-control in volume-controlled ventilation (VCV ) is the most commonly used mode No difference in outcomes between VCV and (PCV Whatever the ventilator mode used, VTs and end-inspiratory plateau pressure should be limited and continuously monitored.

Gas exchange targets Target a PaO2 of at least 60 mm Hg and SaO2 of at least 90% No studies have shown that increasing PaO2 improves outcome Protective ventilation using low VTs may induce respiratory acidosis pH should usually be maintained above 7.2.

Driving pressure Driving pressure ( plateau pressure – PEEP) major determinant of outcome it has been suggested that the mechanical power transferred to the respiratory system from the ventilator plays a key factor in VILI Not only the strain (change in lung volume) but both high flow and respiratory rate are potentially harmful to the lungs

Rescue therapies to improve oxygenation

Recruitment maneuvers  Transient increases in trans-pulmonary pressure in an attempt to open collapsed alveoli. When performing a recruitment manoeuvre the pressure reached at the end of inspiration surpasses the recommended safety thresholds for short time periods Sigh breaths, extended sigh breaths, Increased inspiratory pressures and PEEP, Sustained inflation Staircase Recruitment Manoeuvre . There is currently minimal evidence to recommend a particular method of recruitment. 

Recruitment maneuvers Oxygenation benefits may be short-lived and of uncertain signifiance , There are no studies showing patient outcome benefits, It is uncertain how to differentiate responders from non-responders There is no evidence for when, how often they should be performed There is no evidence of reducing VILI The ART trial found increased mortality with staircase recruitment manoeuvre . Experts made recently a conditional recommendation for using recruitment maneuver ( Fan et al. 2017 ) Recruitment maneuvers can be considered as rescue therapy in the most severely hypoxemic patients No single method can be recommended.  

Proning Advocated for almost 40 years Oxygenation improves dramatically The dorsum of the lung has a larger volume than the anterior and apical areas Better ventilating the dorsal regions of the lung in the prone position improves ventilation, reduces intrapulmonary shunt leading to an improvement in V/Q matching. 

Prone position ventilation

Prone ventilation

Hemodynamics of proning Afterload to the right ventricle is reduced Lower pulmonary vascular resistance Reduced levels of PEEP Improves preload

Prone ventilation

PROSEVA Prone positioning in severe acute respiratory distress syndrome. N Engl J Med. 2013 Jun . MCRCT n =466 patients with severe ARDS (PaO 2 /Fi0 2 ratio <150 mm Hg, with FiO 2 of at least 0.6, PEEP  at least 5 cmH2), and VT 6 ml/kg of IBW) prone-positioning sessions of at least 16 hours duration (n=237) with the supine position (n=229) primary outcome: 28-day mortality lower in the prone group (16% versus 32.8%; P<0.001; hazard ratio for death 0.39, 95% CI 0.25 to 0.63) secondary outcomes: — Unadjusted 90-day mortality lower with prone positioning (23.6% versus 41.0%; P<0.001; hazard ratio 0.44, 95% CI 0.29 to 0.67); NNT=6 — incidence of cardiac arrests higher in the supine group — no difference in ICU LOS or other complications such as pneumothorax — better oxygenation, lower oxygen requirements, and more ventilation-free days in prone group commentary: — highly select group: <15% of all patients with ARDS and <1/3 of screened patients with ARDS underwent randomization,  almost 60% ineligible on the basis of exclusion criteria — benefit may be because of long duration proning — mortality among controls (32.8%) was similar to the mortality of 25 to 40% observed in various trials

PROSEVA trial PROSEVA: Prone Positioning in Severe Acute Respiratory Distress Syndrome Guerin et al for the PROSEVA Study Group. NEJM 2013;368:2159-68. Proning in severe ARDS reduces mortality without an increase in adverse outcomes. Further studies are required to confirm these findings but in the mean time these results are difficult to ignore

Early application of airway pressure release ventilation may reduce the duration of mechanical ventilation in acute respiratory distress syndrome Zhou. Intensive Care Medicine 2017; 43:1648-1659 .

APRV (Airway Pressure Release Ventilation)

ECMO CESAR EOLIA Early transfer to ecmo centre and VV ecmo improve survival

CESAR TRIAL 2009 180 patients – ECMO / Conventional 63% survival at 6months in ECMO group Vs 47% in conventional group Technically flawed due to different levels of care Summary : Mortality difference observed cannot be attributed to ECMO

EOLIA TRIAL 2018 NO MORTALITY DIFFERENCE – ECMO VS CONVENTIONAL VENTILATION CONTROLS – 90% PRONE VENTILATED PRONE VS ECMO 28% OF CONTROLS (SICKER AT RANDOMISATION) MIGRATED TO ECMO WHICH MADE RESULTS DIFFICULT TO INTERPRET SUMMARY(HARDIN &HIBBERT 2018,NEJM)): TRIAL SUPPORTS USE OF ECMO WHO HAVE CLEARLY EXCEEDED CONVENTIONAL VENTILATION AND PRONE POSITION

Sedation The use of sedation improves patient tolerance of positive pressure ventilation and allows resting of respiratory muscles and the reduction of oxygen consumption by these muscles.

Neuro muscular blockers Neuromuscular blocking agent cisatracurium used for 48 hours in severe ARDS patients Improved oxygenation  ( ACURASYS trial) Reduced lung and systemic inflammation Improved patient survival after adjusting for confounding factors

Steroids Clear indications for steroid therapy for diseases that may mimic ARDS include Alveolar hemorrhage due to vasculitis, Drug-induced toxic pneumonia with a lymphocytic pattern Organized pneumonia Acute eosinophilic pneumonia 

Steroids in ARDS Use of steroids in ARDS is unresolved Mortality was significantly higher when steroid therapy was started 2 weeks after the onset Studies showing beneficial outcomes started low dose steroids early in the course of the disease High doses of steroids has been associated with either worse outcomes

Meduri GU et al. 1998 Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA. 1998 Jul 8;280(2):159-65. RCT double blind (placebo controlled) n = 24 inclusion criteria: severe ARDS who failed to improve by day 7 of respiratory failure methylpredisolone VS placebo -> reduction in ICU mortality -> reduced oxygenation requirement -> reduction in MODS score – criticisms: small numbers, differences in baseline characteristics between groups.

Steinberg KP, National Heart, Lung, and Blood Institute Acute Respiratory Distress Syndrome (ARDS) Clinical Trials Network . Efficacy and safety of corticosteroids for persistent acute respiratory distress syndrome. N Engl J Med. 2006 Apr 20;354(16):1671-84. MC RCT, n = 180 methylprednisolone for 14 days with taper versus placebo results: reduced shock symptoms reduced ventilator days improved pulmonary compliance NO improvement in survival increased mortality in patient who had had steroids > 14 days increased neuromuscular weakness What about steroids for ARDS prophylaxis? – increase in ARDS and subsequent mortality (weak trend)

Other adjunct therapies HFOV - High frequency oscillatory ventilation - found harmful Inhaled nitric oxide - no proven benefit Restricted fluid regimen - beneficial

adults with moderate-to-severe ARDS early application of HFOV, as compared with a ventilation strategy of low tidal volume and high positive end-expiratory pressure, does not reduce, and may increase, in-hospital mortality

OSCAR trial 2013 non-blinded intention-to-treat MC RCT 795 patients HFOV versus usual care control group outcomes: -> all cause mortality at 28 days was 41.7% vs  41.1% (P=0.85 chi-square test) Commentary and criticisms: — less hemodynamic compromise, lower airway pressures than OSCILLATE and more protocol variation, possibly due to physician judgement limiting the harm from HFOV settings — HFOV groups received more sedatives and muscle relaxants Conclusion: no mortality difference at 1 month

SUMMARY Bed side echo ,BAL and CT thorax for complete work up HFNC is first line oxygenation method in mild ARDS Do not delay intubation Lung protective ventilation strategy Recruitment during early disease as rescue oxygenation Early proning in case of poor response Consider early ecmo if poor response to proning

This Photo by Unknown Author is licensed under CC BY-NC-ND